Patents by Inventor Trine Lindsted

Trine Lindsted has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapies targeting PD-1, TIM-3, and LAG-3
    Patent number: 11939380
    Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: March 26, 2024
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • Anti-AXL antibodies and compositions
    Patent number: 11807688
    Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: November 7, 2023
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Torben Gjetting, Trine Lindsted, Anton Willer, Anne Worsaae, Maria Carlsen Melander, Janus Schou Jakobsen, Randi Westh Hansen
  • ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20230105714
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: May 11, 2022
    Publication date: April 6, 2023
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20220380470
    Abstract: This invention relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the invention are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: June 7, 2022
    Publication date: December 1, 2022
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • Anti-TIM-3 antibodies and compositions
    Patent number: 11390674
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: July 19, 2022
    Assignee: Symphogen A/S
    Inventors: Trine Lindsted, Torben Gjetting, Gunther Roland Galler, Monika Gad, Michael Monrad Grandal, Klaus Koefoed, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
  • ANTI-FLT3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210317216
    Abstract: This invention relates to anti-FLT3 antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.
    Type: Application
    Filed: April 14, 2021
    Publication date: October 14, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Maria Carlsen Melander, Matteo Riva, Mikkel Wandahl Pedersen, Randi Westh HANSEN
  • Anti-AXL Antibodies and Compositions
    Publication number: 20210269532
    Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 2, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Torben GJETTING, Trine LINDSTED, Anton WILLER, Anne WORSAAE, Maria Carlsen MELANDER, Janus Schou JAKOBSEN, Randi Westh HANSEN
  • ANTI-CD40 ANTIBODIES AND COMPOSITIONS
    Publication number: 20210214454
    Abstract: This invention relates to anti-CD40 antibodies and methods of using them in treating diseases and conditions related to CD40 activity, e.g., cancer.
    Type: Application
    Filed: January 8, 2021
    Publication date: July 15, 2021
    Applicant: SYMPHOGEN A/S
    Inventors: Anton WILLER, Trine LINDSTED, Klaus KOEFOED, Mikkel Wandahl PEDERSEN, Lise Camilla FRÖHLICH
  • COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3
    Publication number: 20200407444
    Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Application
    Filed: April 5, 2018
    Publication date: December 31, 2020
    Applicant: SYMPHOGEN A/S
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
    Publication number: 20190276531
    Abstract: This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.
    Type: Application
    Filed: April 11, 2017
    Publication date: September 12, 2019
    Applicant: SYMPHOGEN A/S
    Inventors: Trine LINDSTED, Torben GJETTING, Gunther Roland GALLER, Monika GAD, Michael Monrad GRANDAL, Klaus KOEFOED, Michael KRAGH, Ivan David HORAK, Thomas BOUQUIN, Mikkel Wandahl PEDERSEN
  • Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
    Patent number: 8323883
    Abstract: Cancer treatment with a combination of an Epidermal Growth Factor Receptor tyrosine kinase inhibitor and an Interleukin-6 inhibitor.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: December 4, 2012
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Raffaella Sordella, Silvia Fenoglio, Trine Lindsted
  • Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
    Patent number: 7947653
    Abstract: Cancer treatment with a combination of an Epidermal Growth Factor Receptor tyrosine kinase inhibitor and an Interleukin-6 inhibitor.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: May 24, 2011
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Raffaella Sordella, Silvia Fenoglio, Trine Lindsted